🇺🇸 FDA
Pipeline program

PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

UC-BCG-2501

Phase 3 small_molecule active

Quick answer

PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL for Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials